Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Curon Medical

This article was originally published in The Gray Sheet

Executive Summary

Initial public offering proceeds increase to $60.2 mil. following exercise of 475,000-share overallotment option, announced Oct. 14. The Sunnyvale, California maker of the Stretta radiofrequency system for gastroesophageal reflux disease initially went public Sept. 22 via an offering of 5 mil. shares at $11 each (1"The Gray Sheet" Oct. 2, 2000, p. 16). A portion of the proceeds will be used to build up the company's sales force for marketing the Stretta system, cleared by FDA via 510(k) in April. Underwriters included lead manager UBS Warburg LLC and co-managers CIBC World Markets and SG Cowen
Advertisement

Related Content

Curon To Beef Up Sales Force For Stretta GERD System With $55 Mil. IPO
Curon To Beef Up Sales Force For Stretta GERD System With $55 Mil. IPO
Advertisement
UsernamePublicRestriction

Register

MT014034

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel